Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended March 31, 2018
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
Device Segment:
AXP	$	685,000	$	65,000			$	750,000
BioArchive		423,000		344,000				767,000
Manual Disposables		233,000		--				233,000
Bone Marrow		38,000		--				38,000
Other		--		--	$	17,000		17,000
Total Device Segment		1,379,000		409,000		17,000		1,805,000
Clinical Development Segment:
Manual Disposables		22,000		--		--		22,000
Bone Marrow		--		23,000		--		23,000
Other		--		17,000		--		17,000
Total Clinical Development		22,000		40,000		--		62,000
Total	$	1,401,000	$	449,000	$	17,000	$	1,867,000

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]

	Remainder of 2018		2019		2020		2021		2022 and After		Total
Service Revenue	$	716,000	$	576,000	$	133,000	$	0	$	0	$	1,425,000
Clinical Revenue		9,000		15,000		15,000		15,000		231,000		285,000
Total	$	725,000	$	591,000	$	148,000	$	15,000	$	231,000	$	1,710,000

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	2018		2017
Vested Series A warrants		404,412		404,412
Unvested Series A warrants (1)		698,529		698,529
Warrants – other		4,030,600		3,725,782
Stock options		1,206,410		334,190
Restricted stock units		416		74,234
Total		6,340,367		5,237,147